Growing pains: Moderna ramps up its child vaccine trial


Growing pains: Moderna ramps up its child vaccine trial

Side effects from the Moderna and Pfizer-BioNTech vaccines among the young population have raised alarms

Robert Langreth and Riley Griffin

Moderna said it would expand an ongoing trial of its coronavirus vaccine in children under 12 years old to gather more safety data amid worries that messenger RNA shots may trigger rare heart side effects.

“The objective is to enrol a larger safety database which increases the likelihood of detecting rarer events,” a Moderna spokesperson said.

Clinical trial timelines are regularly re-evaluated based on regulatory agency discussions and requests, she said, and Moderna expects to have data that would support authorisation in late 2021 or early 2022. The company is discussing a proposal for a bigger trial with the US Food and Drug Administration, she said...

This article is free to read if you register or sign in.

Sunday Times Daily

If you have already registered or subscribed, please sign in to continue.

Questions or problems?
Email or call 0860 52 52 00.

Previous Article